| Novartis Pharma Schweiz AG - Entresto 15 mg/16 mg, filmüberzogenes Granulat | | 69255 | | 02 | | Entresto 15 mg/16 mg | | filmüberzogenes Granulat | | C09DX04 | | Valsartan and Sacubitril | | 21.08.2024 | | |
| | Composition | | Granulat: sacubitrilum 15.18 mg et valsartanum 16.07 mg ut complexus sacubitrili et valsartani natrii hydricus, cellulosum microcristallinum, hydroxypropylcellulosum, magnesii stearas, silica colloidalis anhydrica, talcum, Überzug: copolymerum methacrylatis butylati basicum, talcum, acidum stearicum, natrii laurilsulfas, ad granulatum pro, natrium 2.6 mg. | | Packungsbestandteile | | filmüberzogenes Granulat | | | | Active Agent | Dose | additional_information |
|---|
| Sacubitrilum | 15.18 mg | Granulat | | Valsartan | 16.07 mg | |
| | | | Inactive agents | Dose | additional_information |
|---|
| Acidum Stearicum | | | | Ad Granulatum | | | | Cellulosum Microcristallinum | | | | Copolymerum Methacrylatis Butylati Basicum | | Überzug | | Hydroxypropylcellulosum | | | | Magnesii Stearas | | | | Natrii Laurilsulfas | | | | Sodium | 2.6 mg | | | Silica Colloidalis Anhydrica | | | | Talcum | | | | Valsartani Natrii Hydricus | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | 60 | PR | PR | B | | No |
|
|
